Nonmyeloablative peripheral blood stem cell transplantation for chronic myeloid leukemia in chronic and accelerated phases.
- Author:
Jia-Hua DING
1
;
Yan MA
;
Bao-An CHEN
;
Gang ZHAO
;
Jun WANG
;
Yun-Yu SUN
;
Jian CHENG
;
Ai-Ling SU
;
Wei-Ming DONG
;
Yan ZHANG
Author Information
1. Department of Hematology, Zhongda Hospital, Southeast University, Nanjing 210009, Jiangsu Province, China. JiaHuaDing@medmail.com.cn
- Publication Type:Journal Article
- MeSH:
Adult;
Female;
Graft vs Host Disease;
prevention & control;
Humans;
Leukemia, Myeloid, Accelerated Phase;
therapy;
Leukemia, Myeloid, Chronic-Phase;
therapy;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
methods;
Transplantation Conditioning
- From:
Journal of Experimental Hematology
2008;16(2):373-376
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the effect of nonmyeloablative peripheral blood stem cell transplantation in treatment of chronic myeloid leukemia in chronic phase (CML-CP) and accelerated phase (CML-AP). 24 patients with CML including 16 in CML-CP and 8 in CML-AP were treated with nonmyeloablative conditioning regimen for peripheral blood stem cell transplantation (PBHSCT). The conditioning regimen included fludarabine (30 mg/m(2)x6 d), busulphan [4 mg/(kg.d)x2 d] and CTX [350 mg/(m2.d)x2 d] combined with or without Ara-C. The donors were HLA-identical (n=20) and 5/6 antigen-matched (n=4). The dynamic observation of hematopoietic recovery in all patients was carried out. The results indicated that all the patients were successfully engrafted. The mean time for increase of the number of neutrophils to more than 0.5x10(9)/L and platelet more than 20x10(9)/L were 13 days and 11.5 days respectively. Out of 12 patients, 9 patients showed complete donor chimerism and 3 patients showed mixed chimerism at 30 days after transplantation. At 180 days after transplantation, 18 survival patients showed complete donor chimerism. 18 patients remained alive after a median follow-up length of 24 months (4-48 months). 2 cases died of severe acute GVHD and 1 case died of chronic GVHD, 2 cases died of interstitial pneumonia and 1 case died of relapsed. In conclusions, nonmyeloablative peripheral blood stem cell transplantation is an effective therapeutic method for CML patients in chronic phase and accelerated phase.
